Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)

Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)

Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by system...

Full description

Bibliographic Details
Main Author: Chana L. Glasser, MD
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048917300420
id doaj-0e32eb815f3348b8af0470c2243095d3
record_format Article
spelling doaj-0e32eb815f3348b8af0470c2243095d32020-11-24T22:08:57ZengElsevierLeukemia Research Reports2213-04892017-01-018C192010.1016/j.lrr.2017.10.002Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)Chana L. Glasser, MDTumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C).http://www.sciencedirect.com/science/article/pii/S2213048917300420
collection DOAJ
language English
format Article
sources DOAJ
author Chana L. Glasser, MD
spellingShingle Chana L. Glasser, MD
Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
Leukemia Research Reports
author_facet Chana L. Glasser, MD
author_sort Chana L. Glasser, MD
title Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_short Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_full Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_fullStr Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_full_unstemmed Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_sort tumor lysis syndrome (tls) following intrathecal chemotherapy in a child with acute myelogenous leukemia (aml)
publisher Elsevier
series Leukemia Research Reports
issn 2213-0489
publishDate 2017-01-01
description Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C).
url http://www.sciencedirect.com/science/article/pii/S2213048917300420
work_keys_str_mv AT chanalglassermd tumorlysissyndrometlsfollowingintrathecalchemotherapyinachildwithacutemyelogenousleukemiaaml
_version_ 1725813636085055488

Similar Items